Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
161 Oyster Point Blvd., South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.34K % +214%
Debt-to-equity 9.67 % -72.2%
Return On Equity -33.6 % -162%
Return On Assets -30.7 % -223%
Operating Margin -65.5 % +83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 143M shares +4.18%
Common Stock, Shares, Outstanding 143M shares +4.19%
Entity Public Float 2B USD +33.3%
Common Stock, Value, Issued 1.71M USD +1.48%
Weighted Average Number of Shares Outstanding, Basic 169M shares +23.2%
Weighted Average Number of Shares Outstanding, Diluted 169M shares +19.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 295M USD +191%
Revenue from Contract with Customer, Excluding Assessed Tax 1.27M USD -99.6%
Research and Development Expense 396M USD -2.53%
General and Administrative Expense 101M USD +0.49%
Operating Income (Loss) -481M USD -195%
Nonoperating Income (Expense) 51.5M USD +249%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -420M USD -227%
Earnings Per Share, Basic -2.87 USD/shares -173%
Earnings Per Share, Diluted -2.83 USD/shares -160%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.7M USD -43.4%
Marketable Securities, Current 821M USD -22.4%
Assets, Current 928M USD -24.2%
Property, Plant and Equipment, Net 48.1M USD +20.7%
Operating Lease, Right-of-Use Asset 24.5M USD -10.5%
Other Assets, Noncurrent 50.6M USD +250%
Assets 1.5B USD +15.1%
Accounts Payable, Current 13.9M USD
Employee-related Liabilities, Current 9.56M USD -6.84%
Accrued Liabilities, Current 6.01M USD
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 74.5M USD +7.46%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 41M USD -15.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 116M USD -2.86%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.66M USD -84.5%
Retained Earnings (Accumulated Deficit) -1.32B USD -46.8%
Stockholders' Equity Attributable to Parent 1.39B USD +16.9%
Liabilities and Equity 1.5B USD +15.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -114M USD -93.2%
Net Cash Provided by (Used in) Financing Activities 500M USD +31089%
Net Cash Provided by (Used in) Investing Activities -453M USD -389%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 143M shares +4.19%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -66.5M USD +55.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.3M USD -42.9%
Deferred Tax Assets, Valuation Allowance 376M USD +13%
Deferred Tax Assets, Gross 388M USD +11.6%
Operating Lease, Liability 48.8M USD -12.2%
Payments to Acquire Property, Plant, and Equipment 2.15M USD -22.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -421M USD -258%
Lessee, Operating Lease, Liability, to be Paid 59.7M USD -15.8%
Property, Plant and Equipment, Gross 91.6M USD +12.7%
Operating Lease, Liability, Current 7.77M USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.8M USD +3.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11M USD -28.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +3.3%
Deferred Tax Assets, Operating Loss Carryforwards 89.3M USD +32.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 26.2M USD +35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 13M USD +3.31%
Operating Lease, Payments 11.2M USD -3.61%
Additional Paid in Capital 2.7B USD +29.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.16M USD -78.5%
Deferred Tax Assets, Net of Valuation Allowance 12M USD -18.7%
Share-based Payment Arrangement, Expense 106M USD +1.89%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%